Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis C

Presse Medicale

Volumn 34, Issue 20 II, 2005, Pages 1585-1588

  Rockstroh, J K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; ERYTHROPOIETIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ALOPECIA; ANEMIA; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDICATION; FLU LIKE SYNDROME; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MORTALITY; PANCREATITIS; PREDICTION; REVIEW; SUPERINFECTION; SURVIVAL; THYROID DISEASE; TREATMENT RESPONSE;

EID: 29444437565     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(05)84229-0     Document Type: Short Survey

References (17)

1. Eyster ME, Diamondstone LS, Lien JM et al. Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602-10.
2. Rockstroh JK, Spengler U, Sudhop T et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-8.
3. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128-33.
4. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.
5. Bica I, McGovern B, Dahr RR et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-7.
6. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity - a challenge for hepatologists? J Hepatol 2002; 36: 283-94.
7. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin in combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
8. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon-α 2b + ribavirin compared with interferon-α 2b + ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
9. Perez-Olmeda M, Nunez M, Romero M et al. Pegylated interferon-α 2b + ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-8.
10. Voigt E, Schulz C, Klausen G, Mauss S, Rockstroh JK. Pegylated interferon-α 2b + ribavirin for treatment of chronic hepatitis C in HIV-coinfected patients: a German multicenter trial. 4th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, October 30-November 2, 2004; V-785.
11. Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon-α 2b versus standard interferon-α 2b + ribavirin for chronic hepatitis C in HIV-coinfected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
12. Laguno M, Murillas J, Blanco JL et al. Peg-interferon-α 2b + ribavirin compared with interferon-α 2b + ribavirin for treatment of HIV/HCV-coinfected patients. AIDS 2004; 18: F27-F36.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon- α 2a + ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
14. Chung RT, Andersen J, Volberding P et al. Peginterferon-α 2a + ribavirin versus interferon-α 2a + ribavirin for chronic hepatitis C in HIV-coinfection persons. N Engl J Med 2004; 351: 451-9.
15. Moreno L, Quereda C, Moreno A et al. Pegylated interferon-α 2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.
16. Benhamou Y, DiMartino V, Bochet M et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
17. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003; 362: 1708-13.